Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide

Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide

Hyderabad, India September 2, 2021 and Mississauga, ON, CAN. September 1, 2021 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid® (lenalidomide) capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada.

Read the Full Release

Member Forum

September 13, 2022
Angus Glen Golf Club
Markham, Ontario

MORE INFO

Boot Camp

November 22 - 23, 2022
Virtual Event

MORE INFO

Executive Conference

January 9 - 10, 2023
Montreal Airport Marriott In-Terminal Hotel

MORE INFO

Annual Conference

May 7 - 10, 2023
Sheraton Grand Nashville
Tennessee

MORE INFO